Financial Results
Second Quarter Results
Net loss applicable to common stockholders for the three months ended June 30, 2017 was $21.5 million, or $0.14 per basic and diluted share, compared to a net loss applicable to common stockholders of $13.5 million, or $0.11 per basic and diluted share, for the same period in 2016. Research and development expenses for the three months ended June 30, 2017 totaled $17.9 million compared to $10.1 million for the same period in 2016. General and administrative expense for the three months ended June 30, 2017 and June 30, 2016 were $3.9 million and $3.8 million, respectively.
As of June 30, 2017, our cash, cash equivalents and investments totaled $77.2 million. We currently anticipate our cash position is capable of funding our operations into the fourth quarter of 2018.
ir.iderapharma.com/news-releases/...ond-quarter-2017-financial
noch 77 mille bei 21 verbrauch pro Q